Father’s Day is just around the corner, but many dads won’t be around to celebrate. Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among men in the U.S.
The peer reviewed results published today in the Journal of Urology found that Aureon Laboratories’ Prostate Px+ test is twice as effective as other tools currently available at identifying which patients classified as intermediate-risk have high-risk, life-threatening cancer.
Aureon Laboratories, a developer of predictive tests for cancer care, has been featured in a cable television segment produced by the Yonkers Chamber of Commerce.
Eight studies presented this week at the American Urological Association Annual Meeting suggest that Gen-Probe’s investigational test for the prostate cancer gene PCA3 may address some of the major challenges faced by urologists when diagnosing the disease.
A common prostate-cancer screening test may be largely ineffective, according to two new studies. Scientists in the U.S. and Europe found that the PSA blood test saves few lives and leads to unnecessary treatments for large numbers of men.